2023 was a tricky calendar year with the biopharma field, with various companies downsizing and restructuring their workforces to remain afloat. You can find signs of recovery, as mergers and acquisitions picked up across the pharmaceutical and existence sciences business within the latter part of 2023 and also have continued https://sites.google.com/view/bio-sites/blog